Navigation Links
CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed in Terms of Clinical Safety and Efficacy
Date:9/30/2010

results of SORT-OUT IV, comparing Cordis Corporation's CYPHER(R) Sirolimus-eluting Coronary Stent and Abbott's XIENCE V (R) Everolimus-eluting Stent in the primary endpoint of MACE (major acute coronary events) at nine months. These findings were presented the week commencing 20th September 2010 at the TCT Congress, one of the largest cardiovascular industry events held annually in Washington DC. This study adds to the unmatched body of clinical safety and efficacy data on the CYPHER(R) Stent with this comparison to the more recently approved XIENCE V(R) Stent in a contemporary setting.

"The SORT OUT consortium has used CYPHER(R) Stent as the comparator in a number of studies and to date, no newer stent has proven a benefit over CYPHER(R) Stent in terms of clinical safety or efficacy," said Campbell Rogers, M.D., Chief Scientific Officer and Head, Global Research and Development, Cordis Corporation. "The clinical safety and efficacy of the CYPHER(R) Stent in this real-world randomized study reinforce the excellent sustained clinical outcomes consistently seen over the last 10 years."

The large randomized trial SORT OUT IV included more than 2,600 patients across a wide range of lesion and patient complexity. The study was designed to test whether the XIENCE V(R) stent is non-inferior to the CYPHER(R) Stent. Both drug-eluting stents performed better than planned for the composite endpoint of MACE (4.9 % for XIENCE V(R) Stent vs. 5.2% for CYPHER(R) Stent); these data support the non-inferiority of the XIENCE V(R) stent over the CYPHER(R) stent (non-inferiority p=0.01) . There was no statistically significant difference in key markers of safety including the incidence of cardiac death (1.9% for XIENCE V(R) Stent vs. 1.4% for CYPHER(R) Stent: p=0.31), myocardial infarction, (1.1% for XIENCE V(R) Stent vs. 1.4% for CYPHER(R) Stent: p=0.48), or definite or probable stent thrombosis (0.9% for XIENCE V(R) Stent vs. 0.9% for CYPHER(R) Stent: p=0.83).


'/>"/>

SOURCE Cordis Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up
2. Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent
3. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
4. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
5. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
6. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
9. Pre-clinical Data Show OrbusNeichs Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies
10. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
11. MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Anthem Blue ... that would have required them to obtain their medications ... Consumer Watchdog and Whatley Kallas LLC.  ... Court, alleged that Blue Cross,s mandatory mail order program ... their health and privacy. "This settlement brings ...
(Date:5/23/2013)... , May 23, 2013  Hologic, Inc. ... ), a leading developer, manufacturer and supplier of ... with an emphasis on serving the healthcare needs ... observational study in a U.S. clinical practice comparing ... (breast tomosynthesis) with conventional 2D mammography alone showed ...
(Date:5/23/2013)... , May 23, 2013  Ameritox, the ... selected by Progressive Medical, Inc. to become part ... help clients manage pharmacy costs and improve the ... Medical, a leading pharmacy benefit manager in the ... overall medication compliance and pain management strategy for ...
Breaking Medicine Technology:Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 2Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 3
... 2011 GlaxoSmithKline (GSK) is committed to ensuring that ... and alli. alli is safe and effective when used ... and works locally in the gastro-intestinal tract. GSK continues ... share all relevant information with regulatory agencies. ...
... April 14, 2011 Freedom Innovations, a company ... lower extremity prosthetic devices, today announced a worldwide ... rights to commercialize the world,s first lower extremity ... that operate synergistically.  Developed at the Vanderbilt University ...
Cached Medicine Technology:Freedom Innovations to Commercialize the World's First Actively-Powered, Complete Lower Extremity Prosthesis 2Freedom Innovations to Commercialize the World's First Actively-Powered, Complete Lower Extremity Prosthesis 3
(Date:5/24/2013)... York (PRWEB) May 24, 2013 ... DePuy hip recall continue to move forward in courts ... to documents filed in California’s San Francisco Superior Court ... an expedited trial of her DePuy hip lawsuit is ... DePuy Orthopaedics, Inc., et al., No. CGC11508806; Calif. Super. ...
(Date:5/24/2013)... Western University of Health Sciences’ College of Veterinary ... the next seven years from the American Veterinary Medical ... a magnificent achievement, and one we expected as a ... College of Veterinary Medicine Dean Phillip Nelson, DVM, PhD. ... staff, preceptors, and students that participated in generating the ...
(Date:5/24/2013)... 2013 With Memorial Day Weekend upon us, ... is offering tips to help prevent grill fires throughout ... Association (NFPA) reports that gas grills led to an ... or other solid-fueled grills, meanwhile, caused approximately 1,200 home fires ... Amica Insurance is sharing the following tips from the NFPA ...
(Date:5/24/2013)... E-Dentists.com has announced the launch of their new ... a leading medical Internet marketing agency. , ... focus on providing dentists the help they need to ... keywords. The dental SEO analysis covers a full analysis ... their competitors are doing right. The goal is to ...
(Date:5/24/2013)... May 24 (HealthDay News) -- Drugs commonly used to ... effects that can interfere with vision, according to a ... (PGAs), which are used to reduce eye pressure, have ... changes in eye color, the researchers said, suggesting that ... PGAs. Doctors should be conservative when prescribing ...
Breaking Medicine News(10 mins):Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 2Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 3Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 4Health News:Don’t Get Burned: Five Grilling Tips from Amica Insurance 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2
... for specific treatments, experts say , THURSDAY, March 11 ... pressure and stroke, new British research suggests that extremely ... can greatly increase a person,s risk of stroke. , ... simple hypertension is all that matters, but variability and ...
... Officials at the Natural Products Association (NPA), the leading U.S. trade organization ... between industry proponents Sens. Orrin Hatch (R-UT) and Tom Harkin ... ND) regarding McCain and Dorgan,s recently co-sponsored Dietary Safety Supplement Act (S.3002). , ... ...
... in this week,s issue of the Journal of the ... how he and other physicians who worked in Haiti after ... in the face of a crushing wave of patients and ... in the essay that the team of Johns Hopkins physicians ...
... individuals, DNA to get at causes of disease , ... teams announced this week that they had successfully sequenced ... -- breakthroughs that open the door to a future ... in the inevitable march towards personalized genetic health," said ...
... Ariz. March 11, 2010 Many women live ... treatment, a condition that researchers at the Virginia G. Piper ... targeting specific genes. Improving quality of life and potentially ... time are goals of a new clinical trial at the ...
... abuse testing lab to produce a kit explaining to lawyers how hair alcohol testing works. , ... , , ... ... ...
Cached Medicine News:Health News:Variable Blood Pressure a New Stroke Risk Factor? 2Health News:Variable Blood Pressure a New Stroke Risk Factor? 3Health News:Natural Products Association Welcomes Senate Deal on S.3002 2Health News:Natural Products Association Welcomes Senate Deal on S.3002 3Health News:Hopkins doctor/disaster expert says resource problems in Haiti required ethical decision-making 2Health News:Medicine's Future Could Lie in Each Patient's Genome 2Health News:Medicine's Future Could Lie in Each Patient's Genome 3Health News:Medicine's Future Could Lie in Each Patient's Genome 4Health News:Effort aims to spike breast cancer with new approach 2Health News:Hair Alcohol Test Kit to Help in Third of Care Cases 2Health News:Hair Alcohol Test Kit to Help in Third of Care Cases 3
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
Medicine Products: